Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Deffered Revenue (2022 - 2025)

Historic Non-Current Deffered Revenue for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $349.0 million.

  • Phathom Pharmaceuticals' Non-Current Deffered Revenue rose 824.94% to $349.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $349.0 million, marking a year-over-year increase of 824.94%. This contributed to the annual value of $333.3 million for FY2024, which is 1115.52% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Non-Current Deffered Revenue stood at $349.0 million, which was up 824.94% from $347.0 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $349.0 million during Q3 2025, with a 5-year trough of $109.5 million in Q4 2022.
  • For the 4-year period, Phathom Pharmaceuticals' Non-Current Deffered Revenue averaged around $270.2 million, with its median value being $321.2 million (2024).
  • Per our database at Business Quant, Phathom Pharmaceuticals' Non-Current Deffered Revenue soared by 17374.21% in 2023 and then soared by 803.67% in 2025.
  • Phathom Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $109.5 million in 2022, then surged by 173.74% to $299.8 million in 2023, then grew by 11.16% to $333.3 million in 2024, then increased by 4.72% to $349.0 million in 2025.
  • Its last three reported values are $349.0 million in Q3 2025, $347.0 million for Q2 2025, and $343.8 million during Q1 2025.